In BTC, a 13-15% tyrosine kinase domain mutation rate has been reported and it has been suggested that patients with tumor associated EGFR mutations be preferentially enrolled in clinical trials of EGFR-TKIs [17,18]. Here, EGFR is linked to neoplasm.